// App-Quantinova.ai

AB0759 (2022) : Efficacy of secukinumab in patients with non-radiographic axial spondyloarthritis: analysis by symptom duration and age

Researchers

Presenter

  • A. Deodhar

Principal Investigators

  • D. Poddubnyy

  • R. Blanco

  • S. Hall

  • M. Magrey

  • E. Quebe-Fehling

  • R. Calheiros

  • P. Pertel

  • H. Marzo-Ortega

Medical Centers

  • Oregon Health and Science University, Rheumatology Clinica Division of Arthritis and Rheumatic Diseases, Portland, United States of America

  • Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany

  • Hospital Universitario Marqués de Valdecilla. IDIVAL., Rheumatology and Ophthalmology, Santander, Spain

  • Monash University, Department of Medicine, Alfred Campus, Melbourne, Australia

  • Case Western Reserve University School of Medicine, University Hospitals, Rheumatology Department, Cleveland, Ohio, United States of America

  • Novartis Pharma AG, Immunology, Hepatology and Dermatology Development Unit, Basel, Switzerland

  • NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom

Locations

  • United States

  • Germany

  • Spain

  • Australia

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Non-radiographic axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Axial spondyloarthritis

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

Phase

  • III

Study Id's

  • NCT02696031

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved